SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is seeing heightened activity and community discourse as investors debate its potential in the DePin sector amid ongoing speculation regarding major tech partnerships and future utility. While some users are actively accumulating during price consolidation, others remain skeptical, frequently labeling recent volatility as recurring pump-and-dump behavior.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Janux Therapeutics is currently trading at a deep discount, with its market capitalization falling below its total cash on hand, leading many in the community to argue that the market is essentially valuing its pipeline and proprietary TRACTr/ARM technology at zero. Investors are actively discussing the potential for an eventual rebound, a short squeeze, or an acquisition by a major pharmaceutical partner as the company navigates the market's overreaction to recent clinical data.

MATH is a one stop crypto solution platform which contains MathWallet, MATH VPOS Pool, MathDEX, MATH dApp Store, MATH Staking, MATH Pay, MATH Chain, etc.

MATH

MATH is trending as the community debates its potential for a massive breakout, with many speculating that its low market cap and historical volatility make it a prime candidate for a rapid pump during altcoin season. While some remain optimistic about future exchange listings and utility, others are actively trading the token as a high-risk scalp, often expressing frustration over price stagnation and perceived manipulative sell pressure.

Advanced Energy Industries, Inc. engages in the provision of power electronics conversion products. Its products include AC-DC power supply units, DC-DC conversion, high voltage amplifiers and power supplies, plasma power, controllers, sense, and measurement. The company was founded by Douglas S. Schatz in 1981 and is headquartered in Denver, CO.

Advanced Energy Industries Inc.

Advanced Energy Industries is trending due to the company's Q1 earnings report, which exceeded analyst expectations and demonstrated strong growth in its Data Center business. Investors are actively debating the sustainability of this AI-driven momentum, weighing the company's valuation against its role as a key supplier for critical data center infrastructure buildouts.

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Assembly Biosciences Inc

Assembly Biosciences is capturing investor attention due to intense speculation surrounding a potential buyout by its strategic partner, Gilead, following recent insider accumulation and positive preclinical data. The community remains focused on upcoming clinical catalysts for its antiviral pipeline, though sentiment is split between those bracing for volatility and others holding for a long-term revaluation.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

The iShares China Large-Cap ETF (FXI) is seeing heightened volatility and investor attention as market participants navigate a complex landscape of shifting trade relations with the U.S. and ongoing concerns regarding China's domestic economic stability. The community is actively debating the impact of recent geopolitical headlines, trade framework discussions, and potential stimulus measures on long-term growth versus the risks of structural economic hurdles.

American Exceptionalism Acquisition Corp. A is a blank check company. It was created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on July 11, 2025 and is headquartered in Menlo Park, CA.

American Exceptionalism Acquisition Corp. A - Ordinary Shares - Class A

American Exceptionalism Acquisition Corp. A

Investors are actively speculating on potential acquisition targets for AEXA, with community discourse centered on high-profile possibilities like Starlink, Anduril, and AI-focused tech firms. The stock is trending due to its status as a vehicle for Chamath Palihapitiya, drawing significant retail attention despite the lack of a formal announcement.

Bill Holdings, Inc. engages in the provision of cloud-based software solutions. The firm simplifies, digitizes, and automates complex back-office financial operations for small and midsize businesses. Its software helps customers generate and process invoices, streamline approvals, send and receive payments, sync with their accounting systems and manage their cash. The company was founded by Rene Lacertea in April 2006 and is headquartered in San Jose, CA.

BILL Holdings Inc

Bill.com Holdings Inc

Bill.com Holdings is trending as investors weigh significant price underperformance against its growth potential, with active community discussion focused on potential M&A prospects, the impact of recent activist investor involvement, and the company's valuation relative to its fintech peers.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is attracting attention as a liquid staking protocol with a low market cap, driven by community discussions around a token burn proposal, a new roadmap, and hopes for a deflationary model. Despite recent exchange delisting concerns, retail participants are actively monitoring the asset for potential upside, focusing on its utility as a staking layer and current technical momentum.

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Natera Inc

Natera is experiencing significant market interest driven by recent patent litigation wins and strong institutional support, making it a prominent focus in the oncology diagnostics space. The community is actively discussing the company's competitive positioning in liquid biopsy and MRD testing, with many traders closely monitoring its price momentum and growth potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.read more...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $137.00 at Royal Bank Of Canada

Royal Bank Of Canada increased their price objective on shares of Rhythm Pharmaceuticals from $136.00 to $137.00 and gave the company an "outperform" rating in a research report on Wednesday...

Wells Fargo & Company Boosts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $144.00

Wells Fargo & Company boosted their price target on Rhythm Pharmaceuticals from $143.00 to $144.00 and gave the stock an "overweight" rating in a research note on Wednesday...

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday

Key PointsThe biotech was in the headlines recently after the FDA approved a new indication for its single commercialized drug...

Rhythm Pharmaceuticals Q1 Earnings Call Highlights

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported first-quarter 2026 revenue growth as the company began its U.S. commercial launch of IMCIVREE for acquired hypothalamic obesity (HO) and highlighted new regulatory progress in Europe and Japan.

First-quarter results show continued IMCIVREE growth

Chair...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Announces Earnings Results

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up  After Earnings Beat

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up on Better-Than-Expected Earnings...

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +3.04% and +5.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanguard Group Inc. Purchases 1,214,489 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Vanguard Group Inc. boosted its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 24.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,210,916 shares of the company's stock after buying an ad...

Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Jennison Associates LLC

Jennison Associates LLC grew its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 123.2% in the 4th quarter, according to its most recent disclosure with the...

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.81	--	--	N/A
Q1 '26	-$0.82	-$0.83	-0.61%	MISSED
Q4 '25	-$0.80	-$0.73	9.26%	BEAT
Q3 '25	-$0.71	-$0.82	-15.80%	MISSED
Q2 '25	-$0.67	-$0.75	-11.92%	MISSED

RYTM
Rhythm Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest RYTM News

RYTMRhythm Pharmaceuticals Inc.